Product information
From Health Canada
No match found
No other product was found from this company.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Post Market
Current status date:
2016-08-02
Original market date: See footnote 1
2006-02-13
Product name:
VARIZIG
DIN:
02243342
Product Monograph/Veterinary Labelling:
Date:
2008-01-09
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
CANGENE CORPORATION A SUBSIDIARY OF EMERGENT BIOSOLUTIONS INC.
155 Innovation Drive
Winnipeg
Manitoba
Canada
R3T 5Y3
Class:
Human
Dosage form(s):
Kit
Route(s) of administration:
Intravenous , Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
80:04.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
J06BB03 VARICELLA/ZOSTER IMMUNOGLOBULIN
Active ingredient group (AIG) number:See footnote5
0115174003
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) | 125 UNIT / VIAL |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.